Drug Profile


Alternative Names: EN 241104; GS 4104; GS 4104-002; Ke Wei; Kewei; Oseltamivir phosphate; RO 640796; RO 640796/002; Tamiflu; Tamiflu Dry Syrup

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Australian National University; Gilead Sciences; University of California at Berkeley
  • Developer Chugai Pharmaceutical; HEC Pharm; Roche
  • Class Acetamides; Antivirals; Cyclohexenes; Esters; Small molecules
  • Mechanism of Action Neuraminidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Influenza virus infections

Most Recent Events

  • 16 Dec 2016 Preregistration for Influenza virus infections (In infants, In neonates) in Japan (PO)
  • 16 Dec 2016 Chugai Pharmaceutical files a public-knowledge based application with the Ministry of Health, Labour and Welfare (MHLW), Japan for the approval of oseltamivir for treatment of influenza type A or B virus infection in infants and newborns in Japan
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Influenza-virus-infections(In children, In infants) in Israel (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top